Therapeutic Action
Antimalarial
Source page 355
Loading InternPractice…
Individual generic drug information
Extracted information for ARTESUNATE only.
Antimalarial
Source page 355
Treatment of severe malaria Initial treatment of uncomplicated malaria, when persistent vomiting precludes oral therapy
Source page 355
Extracted information for ARTESUNATE only.
May cause: gastrointestinal disturbances, dizziness, headache, fever, muscle and joint pain, pruritus; rarely rash, delayed haemolytic anaemia (appearing 2 to 3 weeks after treatment, especially in case of hyperparasitaemia and in young children). Pregnancy and breast-feeding: no contra-indication
Source page 358
Extracted information for ARTESUNATE only.
Powder for injection (artesunate), 60 mg vial, plus Solvent: 5% sodium bicarbonate, 1 ml ampoule, plus Diluent: 0.9% sodium chloride, 5 ml ampoule Preparation : For reconstitution (Step-1): add the 1 ml ampoule of 5% sodium bicarbonate into the vial. Shake the vial gently until the powder is dissolved and the solution is clear. For dilution (Step-2): For slow IV (3 to 5 minutes): add 5 ml of 0.9% sodium chloride into the vial to obtain 6 ml of solution containing 10 mg of artesunate per ml For slow IM: add 2 ml of 0.9% sodium chloride into the vial to obtain 3 ml of solution containing 20 mg of artesunate per ml NEVER ADMINISTER BY IV INFUSION.
Source page 355
Child under 6 kg: seek specialist advice. Child 6 kg to < 20 kg: 3 mg/kg/dose Child 20 kg and over and adult: 2.4 mg/kg/dose One dose on admission (H0) then 12 hours after admission (H12) then 24 hours after admission (H24) then, once daily. Administer for at least 24 hours (minimum 3 doses), then, if the patient can tolerate the oral route, change to a full 3-day course of an artemisinin-based combination (ACT). If not, continue parenteral treatment with one dose daily until the patient can tolerate the oral route (do not exceed 7 days of parenteral treatment). The first dose of ACT should be taken 8 to 12 hours after the last injection of artesunate. For information (WHO weight-based dosage): Weight Dose Artesunate 10 mg/ml Artesunate 20 mg/ml per solution for IV solution for IM injection Dose per injection (ml) Dose per injection (ml) (mg) Child 6 to < 20 kg 6 to < 7 kg 20 mg 2 ml 1 ml 7 to < 11 kg 30 mg 3 ml 2 ml 11 to < 14 kg 40 mg 4 ml 2 ml 14 to < 17 kg 50 mg 5 ml 3 ml 17 to < 20 kg 60 mg 6 ml 3 ml Child ≥ 20 kg and adult 20 to < 26 kg 60 mg 6 ml 3 ml 26 to < 30 kg (a) 70 mg 7 ml 4 ml 30 to < 34 kg 80 mg 8 ml 4 ml 34 to < 38 kg 90 mg 9 ml 5 ml 38 to < 42 kg 100 mg 10 ml 5 ml 42 to < 46 kg 110 mg 11 ml 6 ml 46 to < 51 kg 120 mg 12 ml 6 ml 51 to < 55 kg (a) 130 mg 13 ml 7 ml 55 to < 59 kg 150 mg 14 ml 7 ml 59 to < 63 kg 150 mg 15 ml 8 ml 63 to < 67 kg 160 mg 16 ml 8 ml 67 to < 71 kg 170 mg 17 ml 9 ml 71 to < 76 kg 180 mg 18 ml 9 ml 76 to < 80 kg (a) 190 mg 19 ml 10 ml 80 to < 84 kg 200 mg 20 ml 10 ml 84 to < 88 kg 210 mg 21 ml 11 ml nd rd a For patients over 26 kg, a 2 vial must be prepared to obtain the volume needed, a 3 vial for patients th over 51 kg and a 4 vial for patients over 76 kg.
Source pages 356, 357, 358
Extracted information for ARTESUNATE only.
The solution should be clear, do not use if the solution is cloudy or if a precipitate is present. Artesunate 60 mg 2-step formulation and artesunate 1-step formulation are bioequivalent and can be used interchangeably during the course of a treatment. For preparation, use only the solvent/diluent provided by the manufacturer for each formulation. However, to avoid confusion and reduce the risk of preparation errors, it is recommended to use only one formulation per patient per treatment course.
Source page 358
– Below 30 °C Once reconstituted, the solution must be used immediately.
Source page 358
Filter the extracted dose blocks for this individual drug.
2.4 mg/kg/dose
Candidate age grouping · source page 356